JP2023542348A5 - - Google Patents
Info
- Publication number
- JP2023542348A5 JP2023542348A5 JP2023518205A JP2023518205A JP2023542348A5 JP 2023542348 A5 JP2023542348 A5 JP 2023542348A5 JP 2023518205 A JP2023518205 A JP 2023518205A JP 2023518205 A JP2023518205 A JP 2023518205A JP 2023542348 A5 JP2023542348 A5 JP 2023542348A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- disrupted
- population
- cells
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082357P | 2020-09-23 | 2020-09-23 | |
| US63/082,357 | 2020-09-23 | ||
| US202063124429P | 2020-12-11 | 2020-12-11 | |
| US63/124,429 | 2020-12-11 | ||
| US202163225673P | 2021-07-26 | 2021-07-26 | |
| US63/225,673 | 2021-07-26 | ||
| PCT/IB2021/058704 WO2022064428A1 (en) | 2020-09-23 | 2021-09-23 | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542348A JP2023542348A (ja) | 2023-10-06 |
| JP2023542348A5 true JP2023542348A5 (enExample) | 2024-09-24 |
Family
ID=78080385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518205A Pending JP2023542348A (ja) | 2020-09-23 | 2021-09-23 | Ｒｅｇｎａｓｅ－１及び／又はＴＧＦＢＲＩＩを破壊した遺伝子操作されたＴ細胞は機能性及び持続性を改善させた |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20220090012A1 (enExample) |
| EP (2) | EP4176048B1 (enExample) |
| JP (1) | JP2023542348A (enExample) |
| KR (1) | KR20230074515A (enExample) |
| CN (1) | CN116322716A (enExample) |
| AU (1) | AU2021347907A1 (enExample) |
| CA (1) | CA3192280A1 (enExample) |
| ES (1) | ES2993268T3 (enExample) |
| IL (1) | IL301012A (enExample) |
| MX (1) | MX2023003365A (enExample) |
| TW (1) | TW202229545A (enExample) |
| WO (1) | WO2022064428A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113396216A (zh) * | 2019-02-04 | 2021-09-14 | Ksq治疗公司 | 用于改进的免疫疗法的组合基因靶标 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| AU2021286655A1 (en) | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| TW202328444A (zh) * | 2021-07-26 | 2023-07-16 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 用於製造基因工程化ｃａｒ－ｔ細胞之方法 |
| WO2023084399A1 (en) | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
| WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| US20230346836A1 (en) | 2021-12-22 | 2023-11-02 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
| US20230303713A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
| US20230331841A1 (en) | 2022-03-23 | 2023-10-19 | Crispr Therapeutics Ag | Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption |
| WO2024003786A1 (en) | 2022-06-29 | 2024-01-04 | Crispr Therapeutics Ag | Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses |
| WO2024023802A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
| WO2024023801A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene |
| WO2024023804A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene |
| EP4587477A2 (en) * | 2022-09-14 | 2025-07-23 | Ohio State Innovation Foundation | Methods for reprograming exhausted t cells and boosting immune checkpoint blockade therapy for cancer |
| WO2024062388A2 (en) | 2022-09-20 | 2024-03-28 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20 |
| US20240115703A1 (en) * | 2022-10-10 | 2024-04-11 | Crispr Therapeutics Ag | Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignancies |
| WO2024229098A2 (en) * | 2023-05-01 | 2024-11-07 | Wisconsin Alumni Research Foundation | Methods and systems for predicting potent t cell products |
| US12500832B2 (en) | 2023-08-28 | 2025-12-16 | Ciena Corporation | Establishing and advertising co-routed bidirectional paths across multiple domains |
| WO2025126049A2 (en) | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2025137439A2 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
| CN117844811A (zh) * | 2024-03-08 | 2024-04-09 | 上海恒润达生生物科技股份有限公司 | 靶向敲除CD70基因的sgRNA组合物及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| JPWO2010098429A1 (ja) | 2009-02-27 | 2012-09-06 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| EP2970985A1 (en) | 2013-03-14 | 2016-01-20 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| WO2016167957A1 (en) | 2015-04-15 | 2016-10-20 | Saint Louis University | Tumor suppression by mcpip1 |
| JP2017002928A (ja) | 2015-06-05 | 2017-01-05 | 株式会社デンソー | 複数軸駆動用アクチュエータ |
| WO2017002928A1 (ja) | 2015-06-30 | 2017-01-05 | 岸本 忠三 | 新規な肺疾患治療剤および／またはそのスクリーニング方法 |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| EP3389677B1 (en) * | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) * | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| WO2019089884A2 (en) * | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| US20190284553A1 (en) * | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| CN112040987A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| US20220125891A1 (en) | 2018-06-06 | 2022-04-28 | Osaka University | Method for treating and/or preventing regnase-1-related disease |
| WO2020032160A1 (ja) | 2018-08-09 | 2020-02-13 | 国立大学法人大阪大学 | 炎症性腸疾患治療薬およびそのスクリーニング方法 |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| BR112021008041A2 (pt) | 2018-11-07 | 2021-08-10 | Crispr Therapeutics Ag | terapia contra o câncer com células imunitárias anti-cd33 |
| EP3911735A4 (en) * | 2019-01-16 | 2023-07-12 | Beam Therapeutics, Inc. | MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION |
| MX2021013359A (es) * | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| JP6957572B2 (ja) | 2019-09-19 | 2021-11-02 | フランスベッド株式会社 | ベッド装置 |
| CN114929862A (zh) | 2019-11-13 | 2022-08-19 | 克里斯珀医疗股份公司 | 用于制备表达嵌合抗原受体的t细胞的生产方法 |
-
2021
- 2021-09-23 CN CN202180062948.8A patent/CN116322716A/zh active Pending
- 2021-09-23 MX MX2023003365A patent/MX2023003365A/es unknown
- 2021-09-23 IL IL301012A patent/IL301012A/en unknown
- 2021-09-23 ES ES21787042T patent/ES2993268T3/es active Active
- 2021-09-23 AU AU2021347907A patent/AU2021347907A1/en active Pending
- 2021-09-23 EP EP21787042.7A patent/EP4176048B1/en active Active
- 2021-09-23 US US17/483,100 patent/US20220090012A1/en not_active Abandoned
- 2021-09-23 EP EP24162548.2A patent/EP4397321A3/en active Pending
- 2021-09-23 KR KR1020237013253A patent/KR20230074515A/ko not_active Withdrawn
- 2021-09-23 WO PCT/IB2021/058704 patent/WO2022064428A1/en not_active Ceased
- 2021-09-23 CA CA3192280A patent/CA3192280A1/en active Pending
- 2021-09-23 JP JP2023518205A patent/JP2023542348A/ja active Pending
- 2021-09-23 TW TW110135390A patent/TW202229545A/zh unknown
- 2021-10-04 US US17/493,280 patent/US11497773B2/en active Active
- 2021-10-04 US US17/493,253 patent/US11679130B2/en active Active
- 2021-10-04 US US17/493,271 patent/US11679131B2/en active Active
-
2022
- 2022-11-10 US US18/054,521 patent/US11857574B2/en active Active
-
2025
- 2025-02-18 US US19/056,007 patent/US20250179146A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023542348A5 (enExample) | ||
| JP2021087455A5 (enExample) | ||
| US11999773B2 (en) | Anti-BCMA chimeric antigen receptors | |
| CA3133333A1 (en) | Chimeric receptors and methods of use thereof | |
| KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
| CN113614108A (zh) | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 | |
| JP2021522820A5 (enExample) | ||
| AU2023206126B2 (en) | TGF-β receptors and methods of use | |
| IL264144B1 (en) | Antibody 18a2 against claudin and its use | |
| AU2020315796A1 (en) | Fusion polypeptide for immunotherapy | |
| JP2019525771A5 (enExample) | ||
| JP2022512882A5 (enExample) | ||
| RU2017121892A (ru) | Клетка | |
| US20220251168A1 (en) | Dimeric Antigen Receptors (DAR) that Bind BCMA | |
| US20220185882A1 (en) | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same | |
| WO2020172641A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| TW202229358A (zh) | 前列腺癌嵌合抗原受體 | |
| IL304857A (en) | Preparations and methods for treating HER2 POSITIVE cancer | |
| TW202547876A (zh) | Gpc3結合分子 | |
| TW202309294A (zh) | 病毒載體生產系統 | |
| TW202242117A (zh) | 包含多順反子表現卡匣之重組載體及其使用方法 | |
| KR20230090367A (ko) | 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법 | |
| JP2024527537A5 (enExample) | ||
| TWI915404B (zh) | 用於治療ｅｇｆｒ陽性癌症之組合物及方法 | |
| KR102960041B1 (ko) | Egfr 양성 암을 치료하기 위한 조성물 및 방법 |